Medicare AdvantageAdministrativeLow impact
Memantine Products (Revised)
Humana·Geriatrics, Neurology, Psychiatry·Medicare Advantage
Effective date
Jan 1, 2019
We identified it
Jun 25, 2026
Summary
This is a routine policy revision for Humana's Memantine Products pharmacy coverage (revised November 26, 2025). The policy maintains prior authorization requirements for memantine oral solutions, tablets, and extended-release capsules used to treat moderate-to-severe Alzheimer's disease. The primary approval criterion remains unchanged: members must be over 26 years old, OR if 26 or younger, must not have a diagnosis of Autism or Atypical Autism (PDD). No substantive coverage changes are documented in this revision.
Action Required
No immediate action required. This is a routine annual review/revision with no documented coverage changes. Billing and prior authorization staff should verify this is the current version on Humana's website (www.humana.com/PAL) before utilizing. Ensure existing prior authorization workflows for memantine products remain in place for Medicare Advantage members. No system updates or workflow modifications are indicated by this revision.